武汉市胰岛素带量议价政策评析  

Evaluation of Volume-based Procurement of Insulin in Wuhan

作　　者：罗佳 文小桐[1,2] 毛李宁 杨莹 段凤然 王越[1,2] 毛宗福 LUO Jia(School of Public Health,Wuhan University,Wuhan,Hubei,430071,China)

机构地区：[1]武汉大学公共卫生学院,湖北武汉430071 [2]武汉大学全球健康研究中心,湖北武汉430071

出　　处：《医学与社会》2023年第3期114-118,124,共6页Medicine and Society

摘　　要：目的:从科学合理和降价两个维度评析武汉市胰岛素带量议价政策,为全国胰岛素专项采购中选结果落地情况的监测分析提供科学参考。方法:基于湖北省公共资源交易中心线上2018年1月1日-2021年4月30日的药品采购数据,以2018年1月-12月为政策干预前,2020年5月-2021年4月为政策干预后,统计政策前后采购数量、采购金额、日均费用等数值,采用描述性统计方法分析拟合同采购量制定与胰岛素临床使用特征变化。结果:政策实施后除组二G企业和组五A企业胰岛素产品日均费用增加0.01元,其余各议价组内各企业胰岛素产品日均费用均减少,减少0.06元至1.12元不等,变化率范围为-0.64%至-10.97%。约定采购周期实际采购量为1523692支,拟合同约定采购量完成进度为89.43%。从各议价组内各企业来看,组一B企业约定采购量完成进度仅13.81%;组二B企业约定采购量完成进度仅31.82%。结论:武汉市胰岛素带量议价未能充分实现量价挂钩,降价效果较为温和。但武汉市胰岛素带量议价为平稳安全实现胰岛素临床转换替代做出有益探索。Objective: From the 2 dimensions of scientific rationality and price reduction, the volume-based procurement of insulin in Wuhan was evaluated to provide a scientific reference for monitoring and analyzing the national insulin procurement winning results.Methods: Based on the online drug procurement data of the Hubei provincial public resources transaction center from January 1, 2018 to April 30, 2021, the purchasing quantity, purchasing expenditure and daily dose cost before and after the policy was counted using January to December 2018 as the pre-policy intervention and May 2020 to April 2021 as the post-policy intervention, and descriptive statistical methods were used to analyze the formulation of proposed contract purchase quantity and the changes of clinical use characteristics of insulin. Results: After the implementation of the policy, the average daily cost of insulin products decreased by 0.06 yuan to 1.12 yuan, with a change rate ranging from-0.64% to-10.97%, except for enterprises G in group two and enterprises A in group five,where the average daily cost of insulin products increased by 0.01 yuan. The actual purchased quantity during the agreed purchased period was 1523692 pieces. The completion percentage of the purchase quantity agreed in the proposed contract was 89.43%. The completion percentage of enterprise B in group one was only 13.81%. The completion percentage of enterprise B in group two was only 31.82%. Conclusions: Volume-based procurement of insulin in Wuhan failed to realize the volume price linked fully, and the effect of price reduction was mild. However, volume-based procurement of insulin in Wuhan has made a beneficial exploration for the smooth and safe realization of clinical conversion and substitution of insulin.

关 键 词：药物政策 带量议价 胰岛素 武汉 

分 类 号：R-012[医药卫生]